Adhesion is one of the common problems affecting almost 55% to 90% patients followed by surgery. Adhesion is a band of scar tissue formed between organs and tissue after a surgery as a part of a normal healing process. However, when it connects wrong tissues into each other, adhesions may lead to severe clinical symptoms such as pelvic pain, intestinal blockage, infertility and loss of sensation depending on the location and size of the adhesions.
Adhesions are most common after surgeries such as abdominal surgery, thoracic surgery, gynaecological surgery and plastic surgery. After abdominal surgery, bowels and pelvic organs may adhere with each other as a result of adhesion causing risks for small bowel obstruction and severe pain. The various types of adhesions based on their locations are abdominal adhesions, intestinal adhesions, intraperitoneal adhesions and pelvic adhesions.
Some of the anti-adhesion products available in the market are Adept (Baxter), Seprafilm (Genzyme), INTERSEED (Johnson & Johnson) and Surgiwrap (MAST Biosurgery). The market for anti-adhesion products can be segmented on the basis of types of surgery such as abdominal surgery, gynecological surgery and other surgical procedures.
The market for anti-adhesion products is growing due to large number incidences of adhesion associated with various surgeries. Usually 55% to 90% patients undergoing abdominal and gynecological surgeries face adhesion problems. Presently, North America represents the largest market as a number of products have been approved by FDA. Asia-Pacific is experiencing growth as large number of patients are undergoing abdominal and gynecological surgeries. In the coming future the market will witness growth with the introduction of new products with more efficacy.
Some of the major vendors operating in this market are Johnson & Johnson, Baxter International, WL Gore, Anika Therapeutics, Inc., Angiotech Pharmaceuticals, Inc., Genzyme Corporation, LifeCell Corporation and MAST Biosurgery AG.